Cancer, being one of the deadliest disorders globally, has driven researchers to seek safer and more efficacious management options since the last century. Phytoconstituents have been established as safer and more effective alternatives for cancer therapy. However, their efficacy is limited by low solubility and bioavailability, which has prompted research in the field of nanotechnology. Lipid-polymer-based fine particles have recently emerged as a promising alternative due to the advantages they offer over conventional polymeric and lipid nanocarriers by combining the features of both systems. This review aims to provide insights into the delivery of phytoconstituents, drugs, and nucleic acids using lipid-polymer hybrid nanoparticles (LPHNs). Additionally, strategies to optimize LPHNs are presented. Various literature databases, including ScienceDirect, PubMed, Web of Science, and Google Scholar, were explored for literature review and data collection. LPHNs represent a state-of-the-art nanotechnology platform that combines the benefits of polymer- and lipid-based drug delivery methods, offering unparalleled versatility and efficiency in biomedical applications. This review highlights LPHNs as a promising drug delivery vehicle in cancer therapy, discussing their manufacturing and characterization techniques, and showcasing their potential in cancer treatment and beyond. LPHNs demonstrate improved bioavailability for various therapeutic agents; however, clinical success depends on scalable production and regulatory approval. Further research is essential to facilitate their translation into clinical practice.
Tadavi et al. (2026) studied this question.